**Abstract**

**Background:** Injection site reactions and pain associated with long-acting antipsychotics is of interest to healthcare professionals. Safety data of a randomized, double blind (DB), parallel group, multicenter, non-inferiority study (NCT01515423) evaluated paliperidone palmitate 3 month (PP3M) and 1 month (PP1M) injection site reactions and pain.

**Methods:** Patients (N=1429) with schizophrenia were initially treated with PP1M (50--150 mg eq.) in a 17 week open-label (OL) phase. Upon meeting clinical stabilization criteria, patients were randomized 1:1 to PP1M or PP3M in a 48 week DB phase. Patients assigned to PP3M received a 3.5 multiple of the PP1M dose received at week 13; patients in the PP1M group continued to receive the same dose as week 13. Injections occurred every month with PP3M patients receiving placebo injections to maintain blind. Investigators assessed injection site reactions within 30 minutes of each injection. Patients assessed pain using a visual analog scale (VAS; 0 \[no pain\] to 100 \[maximum pain\]).

**Results:** Overall, injections were well-tolerated. Incidence of induration, redness, and swelling were low in the OL (9--12%) and DB (7--13%) phases, and mostly mild in severity. Mean (SD) visual analog scale (VAS) pain scores decreased from 22.0 (21.6) at OL baseline to 19.2 (20.8) at OL week 17. At DB baseline mean (SD) VAS scores for PP3M and PP1M were 19.5 (20.7) and 18.4 (20.4), respectively; at DB endpoint mean (SD) VAS scores were 15.6 (17.9) and 15.5 (18.3) respectively. No notable changes in injection site reactions or pain were observed by injection site location (deltoid vs gluteal) during the OL and DB phases or by final OL dose (50--75 mg eq., 100 mg eq. or 150 mg eq.) of PP1M during the DB phase.

**Conclusion:** Injection site reactions and pain were low and similar between PP1M and PP3M, regardless of last dose of OL PP1M.
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